Ironwood Pharmaceuticals, Inc. - Class A Stock Prediction
AI-powered sentiment analysis and prediction trends for IRWD, updated each market day.
IRWD AI Sentiment
AI predicts Ironwood Pharmaceuticals, Inc. - Class A stock is likely to increase over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Sector
Exchange
Market Cap
$698,964,975
Cap Tier
Employees
100
Headquarters
BOSTON, MA
Listed Since
Feb. 3, 2010
Website
IRWD Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IRWD Volatility
Ironwood Pharmaceuticals, Inc. - Class A has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
